These two biotech disruptors are poised for triple-digit breakout gains.
Phase 1 data demonstrates durable responses and rPFS coupled with a manageable safety profile rPFS of 7.9-8.9 months in heavily pre-treated...
The virtual event will take place on Monday, December 1, 2025, at 4:30 PM ET
Enrollment ongoing for JANX007 and JANX008 Updates on JANX007 and JANX008 expected in the fourth quarter of 2025 ...
Truist Financial analyst initiated coverage with a Buy rating on Janux Therapeutics Inc yesterday and set a price target of $100.00. The company’s shares closed yesterday at $22.76.Elevate Your Investing...
Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Janux Therapeutics Inc today. The company’s shares closed yesterday at $23.31.Elevate Your Investing Strategy: Take advantage...
R&D Day highlighted TRACTr, TRACIr, and ARM pipeline progress and best-in-class potential of novel bispecific ARM platform for autoimmune diseases ...
First patient dosed in the lead collaboration program triggers a $10 million milestone payment to Janux
PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to further differentiate depth...
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor...